武田製藥 TAK 深 滬
已收盤 08-01 16:00:00 美东时间
14.16
+0.440
+3.21%
華盛通- 最 高14.23
- 今 開14.09
- 成交量 627.92万股
- 最 低 14.065
- 昨 收 13.72
- 總市值 442.36亿
- 52周最高 15.53
- 市盈率 靜 64.22
- 換手率 0.20%
- 52周最低 12.524
- 委 比 22.42%
- 總股本 31.24亿
- 歷史最高 17.7461
- 量 比 0.67
- 振 幅 1.20%
- 歷史最低 9.1118
- 每 手 1
- 風險率 0.77%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales
Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, and rare disease drugs.
07-31 04:04
舒沃哲入选国际指南， 迪哲医药抢滩20亿美元市场
转自：贝壳财经 迪哲医药近日公告，公司肺癌靶向药舒沃哲（舒沃替尼片）被纳入美国国立综合癌症网络（NCCN）指南，成为全球唯一纳入国际肺癌指南的EGFR Exo...
07-30 18:18
Takeda Reaffirms FY2025 Guidance, Core Revenue Of ¥4,530B And Core Operating Profit Broadly Flat At ¥1,140B; Core EPS Of ¥485
FY2025 Outlook (unchanged from May 2025)(Billion yen, except percentages and per share amounts)ItemFY2025 FORECASTFY2025 MANAGEMENT GUIDANCE Core Change at CER(Non-IFRS)Revenue4,530.0―Core Revenue
07-30 14:45
Takeda Pharmaceutical Q1 Adj. EPADS $0.52 Beats $0.47 Estimate, Sales $7.66B Beat $7.53B Estimate
Takeda Pharmaceutical (NYSE:TAK) reported quarterly earnings of $0.52 per share which beat the analyst consensus estimate of $0.47 by 11.06 percent. This is a 6.79 percent decrease over earnings of $0.56 per share from
07-30 14:43
Insights Ahead: Takeda Pharmaceutical's Quarterly Earnings
Takeda Pharmaceutical (NYSE:TAK) is gearing up to announce its quarterly earnin...
07-29 23:02
开放与商业：大阪城市文化中的世博密码
从1851年的伦敦到2025年的大阪，世博会已经举办了46届之多，但多次举办世博会的城市，迄今为止只有7座：巴黎7次，伦敦3次，纽约、芝加哥、布鲁塞尔、巴塞罗那...
07-24 13:03
武田制药(TAK.US)TAK-861治疗1型发作性睡病的两项关键性III期研究取得积极结果
武田制药(TAK.US)宣布，Oveporexton(TAK-861)的两项针对1型发作性睡病(NT1)的III期随机、双盲、安慰剂对照研究达到所有主要和次要终点。
07-17 08:07
武田宣布Oveporexton （TAK-861）治疗1型发作性睡病的两项关键性3期研究取得积极结果
- 两项 3 期研究均达到所有主要和次要终点，在 2b 期结果的基础上，所有剂量下的症状均表现出统计学上的显著改善 -Oveporexton 在 ...
07-16 16:19
Takeda sees positive late-stage results for oveporexton in narcolepsy
Takeda Pharmaceutical (NYSE:TAK) said that data from two phase 3 trials on oveporexton for narcolepsy type 1 met all of its primary and secondary endpoints. The stock is up ~3% in pre-market trading M...
07-14 20:47
Takeda's Oveporexton Demonstrates Safety and Efficacy in Global Phase 3 Studies, Paving Way For New Narcolepsy Treatment
Both Phase 3 Studies Met all Primary and Secondary Endpoints Demonstrating Statistically Significant Improvements Across Symptoms at All Doses, Building Upon Phase 2b ResultsOveporexton was Generally Well-Tolerated in
07-14 15:19
